Figure 1.
Factors involved in the development of irAE (A: ECOG PS, B: Albumin). Number of nivolumab administrations (C) and incidence of irAEs by age (D: ≤74 vs. ≥75 years). Comparisons were made using the t-test. −, without irAE; +, with irAE. irAE, immune-related adverse event; ECOG PS, Eastern Cooperative Oncology Group performance status.